Jame Abraham, Chairman and Professor of the Department of Hematology and Medical Oncology at the Cleveland Clinic, shared a post on LinkedIn:
“A study on the treatment of PIK3CA-mutated advanced breast cancer revealed promising results. The combination of inavolisib with palbociclib-fulvestrant showed a notable improvement in overall survival compared to the placebo-palbociclib-fulvestrant combination.
However, it is important to note that certain side effects such as hyperglycemia, stomatitis or mucosal inflammation, gastrointestinal, and ocular toxic effects were more commonly observed with inavolisib. This study sheds light on the potential benefits and risks associated with this treatment approach.”
Title: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer
Journal: NEJM
Authors: Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J. Stout, Tiffany D. Clark, Chunyan Song, Dejan Juric, Nicholas C. Turner
More posts featuring Jame Abraham on OncoDaily.
